Amedisys Inc (AMED) Upgraded at BidaskClub
Amedisys Inc (NASDAQ:AMED) was upgraded by research analysts at BidaskClub from a “sell” rating to a “hold” rating in a note issued to investors on Friday.
A number of other analysts have also recently commented on the stock. Zacks Investment Research cut shares of Amedisys from a “buy” rating to a “hold” rating in a research report on Tuesday, May 2nd. Jefferies Group LLC reaffirmed a “buy” rating and set a $57.00 price target on shares of Amedisys in a research report on Friday, April 28th. Mizuho raised shares of Amedisys from a “neutral” rating to a “buy” rating and set a $65.00 price target on the stock in a research report on Wednesday, May 3rd. Royal Bank Of Canada reaffirmed a “hold” rating and set a $56.00 price target on shares of Amedisys in a research report on Monday, June 5th. Finally, Stephens upped their price target on shares of Amedisys from $50.00 to $54.00 and gave the company an “equal weight” rating in a research report on Thursday, May 4th. Six equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. The company currently has an average rating of “Hold” and an average price target of $56.50.
Shares of Amedisys (AMED) opened at 48.23 on Friday. The firm has a market cap of $1.63 billion, a P/E ratio of 41.22 and a beta of 0.89. The company’s 50-day moving average price is $56.55 and its 200 day moving average price is $54.17. Amedisys has a 52 week low of $34.58 and a 52 week high of $65.91.
Amedisys (NASDAQ:AMED) last issued its quarterly earnings data on Wednesday, July 26th. The health services provider reported $0.62 earnings per share for the quarter, topping the consensus estimate of $0.50 by $0.12. The company had revenue of $378.80 million for the quarter, compared to analysts’ expectations of $380.80 million. Amedisys had a net margin of 2.70% and a return on equity of 13.71%. Amedisys’s revenue for the quarter was up 5.0% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.42 earnings per share. On average, equities analysts anticipate that Amedisys will post $2.21 earnings per share for the current year.
In related news, Director Bruce D. Perkins acquired 2,000 shares of the business’s stock in a transaction dated Thursday, August 3rd. The shares were bought at an average price of $46.60 per share, with a total value of $93,200.00. Following the transaction, the director now directly owns 15,825 shares of the company’s stock, valued at $737,445. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, insider David B. Pearce sold 1,000 shares of the stock in a transaction dated Tuesday, August 8th. The stock was sold at an average price of $50.00, for a total transaction of $50,000.00. Following the transaction, the insider now directly owns 10,488 shares in the company, valued at approximately $524,400. The disclosure for this sale can be found here. 2.80% of the stock is owned by corporate insiders.
Several institutional investors have recently added to or reduced their stakes in AMED. Nationwide Fund Advisors boosted its position in Amedisys by 8.8% in the second quarter. Nationwide Fund Advisors now owns 139,222 shares of the health services provider’s stock worth $8,745,000 after buying an additional 11,268 shares during the period. Ameriprise Financial Inc. boosted its position in Amedisys by 16.6% in the second quarter. Ameriprise Financial Inc. now owns 171,492 shares of the health services provider’s stock worth $10,772,000 after buying an additional 24,458 shares during the period. Teachers Advisors LLC boosted its position in Amedisys by 2.7% in the second quarter. Teachers Advisors LLC now owns 79,605 shares of the health services provider’s stock worth $5,000,000 after buying an additional 2,124 shares during the period. Riverhead Capital Management LLC boosted its position in Amedisys by 75.5% in the second quarter. Riverhead Capital Management LLC now owns 1,931 shares of the health services provider’s stock worth $121,000 after buying an additional 831 shares during the period. Finally, Timpani Capital Management LLC bought a new position in Amedisys during the second quarter worth about $4,924,000. 99.80% of the stock is currently owned by institutional investors.
Amedisys Company Profile
Amedisys, Inc is a healthcare services company. The Company’s segments are Home Health, Hospice, Personal Care and Other. The Company is a provider of home health, hospice and personal care services. As of December 31, 2016, the Company owned and operated 327 Medicare-certified home healthcare centers, 79 Medicare-certified hospice care centers and 14 personal-care care centers in 34 states within the United States and the District of Columbia.
Receive News & Ratings for Amedisys Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys Inc and related companies with MarketBeat.com's FREE daily email newsletter.